Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutathera in Progressive or High-risk Meningioma
NCT03971461Phase 2Active, not recruiting
- Sponsor
- NYU Langone Health
- Start
- May 2019
- Primary completion
- Apr 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in meningioma, sponsored by NYU Langone Health. Started May 2019; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT03971461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971461.